Abstract
Cyclin-dependent kinase inhibitors (CDKIs) represent a new class of anticancer therapeutics. Perturbations in the cell cycle are commonly described in carcinogenesis. This novel class of anticancer therapeutics exploits these perturbations to achieve tumor-specific cytotoxicity. In the last several years, our understanding of cell-cycle regulation has improved with the emerging concepts of cell-cycle-mediated drug resistance and cell-cycle modulation to improve cytotoxic drug efficacy. It is becoming increasingly apparent that CDKIs may improve cytotoxic drug efficacy by functioning as cell-cycle modulators. In this chapter, we review the field of CDKIs as novel anticancer therapeutics, with a focus on their efficacy in drug combinations.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13(12):1501–1512.
Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995;11:211–219.
Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Ann Rev of Pharmacol & Toxicol 1999;39:295–312.
Kaldis P, Russo AA, Chou HS, et al. Human and yeast cdk-activating kinases (CAKs) display distinct substrate specificities. Mol Biol Cell 1998;9(9):2545–2560.
Pardee AB. A restriction point control for normal animal cell proliferation. Proc Natl Acad Sci USA 1974;71:1286–1290.
Malumbres M, Barbacid M. To cycle or not to cycle: A critical decision in cancer. Nat Cancer Revs 2001;1(3):222–231.
Sherr CJ. The Pezcoller Lecture: cancer cell cycles revisited. Cancer Res 2000;60:3689–3695.
Elledge SJ, Harper JW. The role of protein stability in the cell cycle and cancer. Biochim Biophys Acta 1998;1377:M61–70.
Ford HL, Pardee AB. The S-phase: beginning, middle, and end: a perspective. J Cell Biochem 1998;30/31 (Suppl):1–7.
Zhou BS, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000;408:433–439.
Xu B, Kim S-T, Kastan MB. Involvement of BRCA1 in S-phase and G2-phase checkpoints after ionizing radiation. Mol Cell Biol 2001;21:3445–3450.
Falck J, Mailand N, Syljuasen RG, et al. The ATM-Chk2-Cdc25A checkpoint pathway gaurds against radioresistant DNA synthesis. Nature 2001;410:842–847.
Zhou X, Wang X, Hu B, et al. An ATM-independent S phase checkpoint response involves Chk1 pathway. Cancer Res 2002;62:1598–1603.
Ford HL, Pardee, AB. Cancer and the cell cycle. J Cell Biochem 1999;32/33 Suppl:166–172.
Anderson SSL. Spindle assembly and the art of regulating microtubule dynamics by MAPs and stathmin/Op18. Trends Cell Biol 2000;10:261–267.
Rudner AD, and Murray AW. The spindle assembly checkpoint. Curr Opin Cell Biol 1996;8:773–80.
Nicklas RB. How cells get the right chromosome. Science 1997;275:632–637.
Reed JC, Bischoff JR. Ringing chromosomes through cell division—and survivin’ the experience. Cell 2000;102:545–548.
Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001;7:542–547.
O’Connor DS, Wall NR, Porter ACG, et al. A p34cdc2 survival checkpoint in cancer. Cancer Cell 2002;2:43–54.
Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266:1821–1828.
Harper J, Elledge SJ. Cdk inhibitors in develpment and cancer. Curr Opin Genet Dev 1996;6:56–64.
Chen Y-N, Sharma SK, Ramsey TM, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA 1999;96:4325–4329.
Senderowicz AM. Cyclin-dependent kinases as targets for cancer therapy. In: (Giaccone G, Schilsky R, Sondel G, eds), Cancer Chemotherapy and Biological Response Modifiers, Annual 20. Elsevier Science, Amsterdam: 2002;169–188.
Losiewicz MD, Carlson BA, Kaur G, et al. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 1994;201:589–595.
Carlson BA, Dubay MM, Sausville EA, et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase CDC2 and CDK4 in human breast carcinoma cells. Cancer Res 1996;56:2973–2978.
Carlson BA, Pearlstein RA, Naik RG, et al. Inhibition of CDK2, CDK4 and CDK7 by flavopiridol and structural anologs. Proc Am Assoc Cancer Res 1996;36.
Dumant JA. HMR Report No. B/98/0189/R, B/98/0188/R, 8/98/0187/R. HMR Oncology 1996.
Konig A, Schwartz GK, Mohammad RM, et al. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia cell lines. Blood 1997;90:4307–4312.
Byrd JC, Shinn, C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence of functional p53. Blood 1998;92:3804–3816.
Arguello F, Alexander M, Sterry JA, et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 1998;91:2482–2490.
Cartee L, Wang Z, Decker RH, et al. The cyclin-dependent kinase inhibitor (CDKI) Flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells. Cancer Res 2001;61(6):2583–2591.
Bible KC, Kaufmann SH. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 1996;56(21):4856–4861.
Schrump DS, Mathews W, Chen GA, et al. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cell lines. Clin Cancer Res 1998;4:2885–2890.
Carlson B, Lahusen T, Singh S, et al. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 1999;59(18):4634–4641.
Drees M, Dengler WA, Roth T, et al. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res 1997;3(2):271–279.
Patel V, Senderowicz AM, Pinto, D, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 1998;102(9):1674–1681.
Thomas JP, Tutsch KD, Cleary JF, et al. Phase I clinical and pharmacokinetic trial of cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002;50:465–472.
Senderowicz AM, Headlee D, Stinson SF, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998;16(9):2986–2999.
Stadler WM, Vogelzang NJ, Amato R, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol 2000;18(2):371–375.
Shapiro GI, Patterson A, Lynch C, et al. A phase II trial of flavopiridol in patients with stage IV non-small cell lung cancer. Proc Amer Soc Clin Oncol 1999: Abstract 2013.
Schwartz GK, Ilson D, Saltz L, Howard OM, Neuberg DS, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001;19(7):1985–1992.
Lin TS, Howard OM, Neuberg DS, et al. Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leuk Lymphoma 2002;43(4):793–797.
Burdette-Radoux S, Tozer RG, Lohmann R, et al. NCIC CTG phase II study of flavopiridol in patients with previously untreated metastatic malignant melanoma. Proc Amer Soc Clin Oncol 2002;Abstract 1382.
Bennett P, Mani S, O’Reilly S, et al. Phase II trial of flavopiridol in metastatic colorectal cancer: preliminary results. Proc Amer Soc of Clin Oncol 1999;Abstract 1065.
Takahashi I, Saitoh Y, Yoshida M. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. Purification, physico-chemical properties, structural determination and biological activities. J Antibiot 1989;42:571–576.
Tamoaki T, Nakano H. Potent and specific inhibitors of PKC of microbial origin. Biotech 1990;8:732–735.
Seynaeve CM, Stetter-Stevenson M, Sebers S, et al. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 1993;53(9):2081–2086.
Akinaga S, Nomura K, Gomik, et al. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoind carcinoma, A431 cells. Cancer Chemother Pharmacol 1994;33(4):273–280.
Kawakami K, Futami H, Takahara J, et al. UCN-01, 7-hydroxylstaurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem Biophys Res Commun 1996;219(3):778–783.
Akiyama T, Yoshida T, Tsujita T, et al. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as the induction of CDK inhibitor p21/CIP/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res 1997;57(8):1495–1501.
Fan G, Steer CJ. The retinoblastoma gene product is a negative modulator of the apoptotic pathway. Adv Enzyme Regul 1996;36:283–303.
Hsueh CT, Kelsen D, Schwartz GK. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. Clin Cancer Res 1998;4(9):2201–2206.
Graves PR, Yu L, Schwarz JK, et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000;275(8):5600–5605.
Busby EC, Leistritz DF, Abraham RT, et al. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000;60(8):2108–2112.
Yu Q, Rose, JH, Zhang H, et al. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G2-M Checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res 2002;62:5743–5748.
Sausville EA, Lush RD, Headlee D, et al. Phase I trial of 72-hour continuous infusion of UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001;19(8):2319–2333.
Fuse E, Tanii H, Kurata N, et al. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res 1998;58:3248–3253.
Sausville EA, Lush RD, Headlee D, et al. Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models. Cancer Chemother Pharmacol 1998;42(Suppl):S54–S59.
Tamura T, Sasaki Y, Minami H, et al. Phase I study of UCN-01 by 3 hour infusion. Proc Amer Soc Clin Oncol 1999;18:159a.
Dees EC, O’Reilly S, Figg WD, et al. A phase I and pharmacologic study of UCN-01, a protein kinase C inhibitor. Proc Amer Soc Clin Oncol 2000;19:205a.
Mutter R, Wills M. Chemistry and clinical biology of the bryostatins. Bioorg Med Chem 2000;8:1841–1860.
Wender PA, Cribbs CM, Koehler KF, et al. Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C. Proc Natl Acad Sci USA 1988;85:7197–7201.
Kraft AS, Smith JB, Berkow RL. Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc Natl Acad Sci USA 1986;83:1334–1338.
Hennings H, Blumberg PM, Pettit GR, et al. Bryostatin-1, an activator of protein kinase C inhibits tumor promotion by phorbol esters in Sencar mouse skin. Carcinogenesis 1987;9:1343–1346.
Isakov N, Galron D, Mustelin T, et al. Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C. J Immunol 1993;150(4):1195–1204.
Lee HW, Smith L, Pettit GR, et al. Ubiquitination of protein kinase C-alpha and degradation by the proteasome. J Biol Chem 1996;271:20,973–20,976.
Asiedu C, Biggs J, Lilly M, et al. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin-1 correlates with the dephosphorylation of cyclin-dependent kinase 2.Cancer Res 1995;55:3716–3720.
Vrana JA, Saunders AM, Chellappan SP, et al. Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937). Differentiation 1998;63:33–42.
Vrana, JA, Kramer LB, Saunders AM, et al. Inhibition of protein kinase C activator-mediated induction of p21cip1 and p27kip1 by deoxycytidine analogs in human leukemia cells: relationship to apoptosis and differentiation. Biochem Pharmacol 1999;58:121–131.
Koutcher JA, Motwani M, Dyke JP, et al. The in vitro effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow. Clin Cancer Res 2000;6:1498–1507.
Hickman PF, Kemp GJ, Thompson CH, et al. Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study. Br J Cancer 1995;72:998–1003.
Prendiville J, Crowther D, Thatcher N, et al. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 1993;68:418–424.
Philip, PA, Rea D, Thavasu P, et al. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst 1993;85:1812–1818.
Jayson GC, Crowther D, Prendiville J, et al. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24-hour intravenous infusion. Br J Cancer 1995;72:461–468.
Varterasian ML, Mohammad RM, Eilender DS, et al. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. J Clin Oncol 1998;16:56–62.
Propper DJ, Macaulay V, O’Bryne KJ, et al. A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer 1998;78:1337–1341.
Gonzalez, R, Ebbinghaus S, Henthorn TK, et al. Treatment of patients with metastatic melanoma with bryostatin-1—a phase II study. Melanoma Res 1999;9:599–606.
Bedikian AY, Plager C, Stewart JR, et al. Phase II evaluation of bryostatin-1 in metastatic melanoma. Melanoma Res 2001;11:183–188.
Pagliaro L, Daliani D, Amato R, et al. A phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer 2000;89:615–618.
Zonder JA, Shields AF, Zalupski M, et al. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. Clin Cancer Res 2001;7:38–42.
Blackhall FH, Ranson M, Radford JA, et al. A phase II trial of bryostatin 1 in patients with non-Hodgkin’s lymphoma. Br J Cancer 2001;84:249–254.
Brockstein B, Samuels B, Humerickhouse R, et al. Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer. Invest New Drugs 2001;19:249–254.
Luria SE, Delbruck M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 1943;28:491.
DeVita VT. Principles of cancer management: chemotherapy. In: (DeVita VT, Rosenberg SA, Hellman S, eds), Cancer: Principles and Practice of Oncology, Lippincott-Raven, Philadelphia: 1997;333-347.
Goldie JH, Coldman AJ. A model for tumor response to chemotherapy: an integration of the stem cell and somatic mutation hypotheses. Cancer Invest 1985;3(6):553–564.
Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63(11-12):1727–1733.
Ritke MK, Rusnak JM, Lazo JS, et al. Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells. Mol Pharmacol 1994;46:605–611.
Evans DL, Dive C. Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res 1993;53:2133–2139.
Elledge RM, Gray R, Mansour E, et al. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 1995;87(16):1254–1256.
Rusch V, Klimstra D, Venkatraman E, et al. Aberent p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995;55:5038–5042.
Eliopoulos AG, Kerr DJ, Herod J, et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 1995;11:1217–1228.
Righetti SC, Della Torre G, Pilotti S, et al. A comparative study of p53 gene mutations, protein accumulation and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996;56(4):689–693.
Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 1972;26:239–257.
Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1990;68:251–306.
Dive C, Evans CA, Whetton AD. Induction of apoptosis-new targets of cancer chemotherapy. Semin Cancer Biol 1992;3:417–427.
Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999;117(9):2941–2953.
Vaux DL, Haecker G, Strasser A. An evolutionary perspective on apoptosis. Cell 1994;76:777–779.
Stewart BW. Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst 1994;86:1286–1296.
Hockenbery D. Defining apoptosis. Am J Pathol 1995;146:16–19.
Martin SJ, Green DR. Protease activation during apoptosis. Death by a thousand cuts? Cell 1995;82:349–352.
Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980. 284:555–556.
Lazebnik YA, Takahashi A, Moir RD, et al. Studies of the lamin proteinase reveal multiple parallel biochemical pathways during apoptotic execution. Proc Natl Acad Sci USA 1995;92:9042–9046.
Kaufmann SH, Desnoyers S, Ottaviano Y, et al. Specific proteolytic cleavage of poly (ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993;53:3976–3985.
Lazebnik YA, Kaufman SH, Desnoyers S, et al. Cleavage of poly (ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994;371:346–347.
Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37–43.
Neamati N, Fernandez A, Wright S, et al. Degradation of lamin B1 precedes oligonucleosomal DNA fragmentation in apoptotic thymocytes and isolated thymocyte nuclei. J Immunol 1994;154:3788–3795.
Seller WR, Fisher DE. Apoptosis and cancer drug targeting. J Clin Invest 1999;104(12):1655–1661.
Fisher, DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78:539–542.
Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994;73:2013–2026.
Bellamy CO, Malcolmson RD, Harrison DJ, et al. Cell death in health and disease: the biology and regulation of apoptosis. Semin Cancer Biol 1995;6:3–16.
McDonnell TJ, Meyn RE, Robertson LE. Implications of apoptotic cell death regulation in cancer therapy. Semin Cancer Biol 1995;6:53–60.
Eastman A. Survival factors, intracellular signal transduction, and the activation of endonucleases in apoptosis. Semin Cancer Biol 1995;6:45–52.
Lowe SW, Ruley HE, Jact T, et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957–967.
Nabeya Y, Loganzo F. Maslak P, et al. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer 1994;64:1–10.
Ibardo AM, Huang Y, Fang G, et al. Bcl-xl overexpression inhibits taxol-induced yama protease activity and apoptosis. Cell Growth and Differ 1996;7:1087–1094.
Datta R, Manome Y, Taneja N, et al. Overexpression of Bcl-xl by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth and Differ 1995;6:363–370.
Gajewski TF, Thompson CB. Apoptosis meets signal transduction: elimination of a BAD influence. Cell 1996;87(4):589–592.
Jarvis WD, Grant S. Protein kinase C targeting in antineoplastic treatment strategies. Invest New Drugs 1999;17(3):227–240.
Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323–331.
El-Diery WS, Harper JW, O’Connor PM, et al. Waf1/Cip1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169–1174.
Brugaralas J, Chandrasekaran C, Gordon JI, et al. Radiation-induced cell arrest compromised by p21 deficiency. Nature 1995;377:552–557.
Chan TA, Hwang PM, Hermeking J, et al. Cooperative effects of genes controling the G2/M checkpoint. Genes Dev 2000;14:1584–1588.
Bunz F, Dutriaux A, Lengauer C, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497–1501.
Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104(3):263–269.
Yu J, Zhang L, Hwang PM, et al. Identification and classification of p53-regulated genes. Proc Natl Acad Sci USA 1999;96:14,517–14,522.
Clarke AR, Gledhill S, Hooper ML, et al. p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. Oncogene 1994;9:1767–1773.
Waldman T, Yongyang Y, Diollehay L, et al. Cell cycle arrest versus cell death in cancer therapy. Nat Med 1997;3:1034–1036.
Shah MA, Schwartz GK. Cell Cycle mediated drug resistance: An emerging concept in cancer therapy. Clin Cancer Res 2001;7(8):2168–2181.
Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997;48:353–374.
Schiff PB, Fant J, and Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277(5698):665–667.
Schiff PB, Horwitz SB. Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins. Biochemistry 1981;20(11):3247–3252.
Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980;77(3):1561–1565.
Yoo YD, Park JK, Choi JY, et al. CDK4 down-regulation induced by paclitaxel is associated with G1 arrest in gastric cancer cells. Clin Cancer Res 1998;4(12):3063–3068.
Long BH, Fairchild CR. Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res 1994;54(16):4355–4361.
Brown T, Havlin K, Weiss G, et al. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991;9(7):1261–1267.
Donaldson KL, Goolsby GL, Kiener PA, Wahl AF. Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell Growth Differ 1994;5(10):1041–1050.
Ling YH, Yank Y, Cansoli U, et al. Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with Taxol. Int J Cancer 1998;75:925–932.
Clute P, Pines, J. Temporal and spatial control of cyclin B1 destruction in metaphase. Nat Cell Biol 1999;1:82–86.
Yu D, Jing T, Liu B, et al. Overexpression of ErbB2 blocks taxol-induced apoptosis by upregulation of p21Cip1 which inhibits p34Cdc2 kinase. Mol Cell 1998;2:581–591.
Donaldson KL, Goolsby GL, Wahl AF. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int J Cancer 1994;57(6):847–855.
Blagosklonny MV, Giannakakou P, El-Deiry WS, et al. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 1997;57(1):130–135.
Chen CY, Faller DV Phosphorylation of Bcl-2 protein and association with p21Ras in Ras-induced apoptosis. J Biol Chem 1996;271(5):2376–2379.
Blagosklonny MV, Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 1999;83(2):151–156.
Trielli MO, Andreassen PR, Lacroix FB, et al. Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific related mortality of transformed cells. J Cell Biol 1996;135:689–700.
Wang T-H, Wang H-S, Soong Y-K. Paclitaxel-Induced cell death. Cancer 2000;88:2619–2628.
Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 1999;5(7):1876–1883.
Kaubisch A, Kelsen DP, Saltz L, et al. A phase I trial of weekly sequential bryostatin (Bryo) and paclitaxel in patients with advanced solid tumors. Proc Amer Soc Clin Oncol 1999;18:Abstract 639.
Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 1997;57:3375–3380.
Wang S, Wang Z, Boise L, et al. Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis. Biochem Biophys Res Commun 1999;259(1):67–72.
Schmitt E, Cimoli G, Steyaert A, et al. Bcl-xL modulates apoptosis induced by anticancer drugs and delays DEVDase and DNA fragmentation-promoting activities. Exp Cell Res 1998;240(1):107–121.
Wang S, Wang Z, Boise LH, et al. Bryostatin-1 enhances paclitaxel induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xl. Leukemia 1999;13(10):1564–1573.
Wang S, Guo C, Castillo A, et al. Effect of bryostatin-1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937). Biochem Pharmacol 1998;56(5):635–644.
Schwartz GK, O’Reilly E, Ilson D, et al. Phase I and pharmacokinetic study of paclitaxel followed by bryostatin-1 in patients with advanced solid tumors. J Clin Oncol 2001;20:257–2170.
Wall ME, Wani MC, Cook CE, et al. Plant anti-tumor agents 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966;88:3888–3890.
Slichenmeyer WJ, Rowinsky EK, Donehower RC, et al. The current status of camptothecin analogues as antitumor agents. JNCI 1993;85:271–291.
Li LH, Fraser TJ, Olin EJ, et al. Action of camptothecin on mammalian cells in culture. Cancer Res 1972;32(12):2643–2650.
Creemers CJ, Lund B, Verwij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994;20:73–96.
Hsiang Y-H, Hertzberg R, Hecht S, et al. Camptothecin induces protein-linked DNA breaks via mammalian Topoisomerase I. J Biol Chem 1985;260:14,873–14,878.
Hsiang Y-H, Lihou MG, Liu F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by Camptotheicin. Cancer Res 1989;49:5077–5082.
Sane AT, Bertrand R. Caspase inhibition in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient G1 arrest followed by necrotic cell death. Cancer Res 1999;59(15):3565–3569.
Tsao YP, D’Apra P, Liu LF. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res 1992;52(7):1823–1829.
Kohn EA, Ruth ND, Brown MK, et al. Abrogation of the S phase DNA damage checkpoint results in S phase progression of premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. J Biol Chem 2002;277(29):26,553–26,564.
Weller M, Winter S, Schmidt C, et al. Topisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax, and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone. Int J Cancer 1997;73(5):707–714.
Shimizu T, O’Connor PM, Kohn KW, et al. Unscheduled activation of cyclin B1/cdc2 kinase in human promyelocytic leukemia cell line HL60 cells ungroing apoptosis induced by DNA damage. Cancer Res 1995;55:228–231.
Saltz LB, Konowitz J, Kemeny NE, et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996;14(11):2959–2967.
Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal carcinoma. Irinotecan Study Group. New Engl J Med 2000;343(13):905–912.
Saijo N. Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecan injection) in Japan. Ann NY Acad Sci 1996;803:292–305.
Waldman T, Kinzler KW, Vogelstein B. P21 is necessary for the p53 mediated G1 arrest in human cancer cells. Cancer Res 1995;55:5187–5195.
Motwani M, Jung C, Sirotnak FM, et al. Augmentation of apoptosis and tumor regressions by flavopiridol in the presence of CPT-11 in HCT116 colon cancer monolayers and xenografts. Clin Cancer Res 2001;7:4209–4219.
Shah MA, Kortmansky J, Gonen M, et al. A phase I/pharmacologic study of weekly sequential irinotecan (CPT) and flavopiridol. Proc Am Soc Clin Oncol 2002: Abstract 373. Available at: http://www.asco.org. Accessed August 11, 2003.
Goldwasser F, Shimuzu T, Jackman J, et al. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res 1996;56(19):4430–4437.
Shao RG, Cao CX, Shimizu T, et al. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 1997;57(18):4029–4035.
Jones CB, Clements MK, Wasi S, et al. Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G2 arrest. Cancer Chemother Pharmacol 2000;45:252–258.
Nieves-Neira W, Pommier Y. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI anticancer drugs screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2, and caspace pathways. Int J Cancer 1999;82:396–404.
Tse A, Schwartz GK. Abrogation of the G2/M checkpoint by 7-hydroxystaurosporine (UCN-01) on SN-38 treated cells: a strategy for targeting tumors with defective cell cycle checkpoints. Am Assoc Cancer Res 2002.
Bozko P, Larsen AK, Raymond E, et al. Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status. Acta Biochimica Polonica 2002;49(1):109–119.
Allegra CJ, Grem JL. Antimetabolites. In: (DeVita VT, Hellman S, and Rosenberg SA, eds), Cancer: Principles and Practice of Oncology. Lippincott-Raven: Philadelphia: 1997;432–452.
Santi DV, McHenry CS, Raines RT, et al. Kinetics and thermodynamics of the interaction of 5-fluoro-2′-deoxyuridylate with thymidylate synthase. Biochemistry 1987;26(26):8606–8613.
van Triest B, Pinedo HM, van Hensbergen, et al. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res 1999;5(3):643–654.
Grem JL, Nguyen D, Monahan DP, et al. Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells. Biochem Pharmacol 1999;58(3):477–486.
Takeda H, Haisa M, Naomoto Y, et al. Effect of 5-fluorouracil on cell cycle regulatory proteins in human colon cancer cell line. Jpn J Cancer Res 1999;90(6):677–684.
Farnham PJ, and Schimke RT. Transcriptional regulation of mouse dihydrofolate reductase in the cell cycle. J Biol Chem 1985;260(12):7675–7680.
Ayusawa D, Shimizu K, Koyama H, et al. Cell-cycle-directed regulation of thymidylate synthase messenger RNA in human diploid fibroblasts stimulated to proliferate. J Mol Biol 1986;190(4):559–567.
Kortmansky J, Shah MA, Kemeny N, et al. A phase I/Pharmacologic study of UCN-01 in combination with 5-fluorouracil in patients with advanced solid tumors. In NCI-EORTC Conference, 2001, Miami, FL.
Sorenson CM, Eastman A. Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double strand breaks. Cancer Res 1988;48:4484–4488.
Schlegel R, Belinsky GS, Harris MO. Premature mitosis induced in mammalian cells by the protein kinase inhibitors 2-aminopurine and 6-dimethylaminopurine. Cell Growth Differ 1990;1(4):171–178.
Demarcq C, Bunch RT, Creswell D, et al. The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth Differ 1994;5(9):983–993.
Shi Y, Frankel A, Radvanyi LG, et al. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 1995;55(9):1982–1988.
O’Dwyer PJ, Johnson SW, Hamilton TC. Cisplatin and its analogues. In: (DeVita VT, Hellman S, and Rosenberg SA, eds), Cancer: Principles and Practice of Oncology, Lippincott-Raven, Philadelphia: 1997;467–483.
Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990;40(10):2353–2362.
Judson PL, Watson JM, Gehrig PA, et al. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Cancer Res 1999;59(10):2425–2432.
Kaufmann WK, Paules RS. DNA damage and cell cycle checkpoints. FASEB 1996;10:238–247.
Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996;56:892–898.
Brown R, Clugson C, Burns P, et al. Increased accumulation of p53 protein in cisplatin-resistant cell lines. Int J Cancer 1993;55:678–684.
Perego P, Giarola M, Righetti SC, et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996;56:556–562.
Zaffaroni N, Slivertrini R, Orlandi L, et al. Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and-resistant human ovarian cancer cells. Br J Cancer 1998;77(9):1378–1385.
Monks A, Horris ED, Vaigro-Wolff A, et al. UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines. Invest New Drugs 2000;18(2):95–107.
Bunch RT, Eastman A. 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. Cell Growth Differ 1997;8(7):779–788.
Husain A, Yan XY, Rosales N, et al. UCN-01 enhances CDDP cytotoxicity in ovarian cancer cells independent of p53 gene status and abrogation of G2 block. Clin Cancer Res 1997;4:2089–2097.
Sugiyama K, Shimizu M, Akiyama T, et al. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation. Int J Cancer 2000;85(5):703–709.
Huang P, Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol 1995;22:19–25.
Plunkett W, et al. Gemcitabine: metabolism, mechanisms of action and self-potentiation. Semin Oncol 1995;22:3–10.
Huang P, Chubb S, Hertel LW, et al. Action of 2′2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51:6110–6117.
Cappella P, Tomasoni D, Faretta M, et al. Cell cycle effects of gemcitabine. Int J Cancer 2001;93:401–408.
Huang P, Plunkett W. Fludarabine-and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 1995;36:181–188.
Chen M, Hough AM, Lawrence TS, et al. The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization. Cancer Chemother Pharmacol 2000;45:369–374.
Galmarini CM, Clarke ML, Falette N, et al. Expression of non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer 2002;97:439–445.
Jung CP, Motwani MV, Schwartz GK. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 2001;7:2527–2536.
Zhou BS, Tsai P, Ker R, et al. Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis 1998;16:43–49.
Goan YG, Zhou BS, Hu E, et al. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in human KB cancer cell line. Cancer Res 1999;59:4204–4207.
Matranga CB, Shapiro GI. Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase. Cancer Res 2002;62:1707–1717.
Banker DE, Groudine M, Willman CL, et al. Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents. Leuk Res 1998;22:221–239.
Shi Z, Azuma A, Sampath D, et al. S-phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res 2001;61:1065–1072.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Shah, M.A., Schwartz, G.K. (2005). Cyclin-Dependent Kinase Inhibitors in Combination Chemotherapy. In: Schwartz, G.K. (eds) Combination Cancer Therapy. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1385/1-59259-864-1:027
Download citation
DOI: https://doi.org/10.1385/1-59259-864-1:027
Publisher Name: Humana Press
Print ISBN: 978-1-58829-200-1
Online ISBN: 978-1-59259-864-9
eBook Packages: MedicineMedicine (R0)